Trade Lyell Immunopharma, Inc. - LYEL CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.62 |
| Open | 1.64 |
| 1-Year Change | -44.78% |
| Day's Range | 1.59 - 1.67 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 1.60 | 0.02 | 1.27% | 1.58 | 1.72 | 1.55 |
| Jul 24, 2024 | 1.59 | -0.04 | -2.45% | 1.63 | 1.69 | 1.58 |
| Jul 23, 2024 | 1.66 | 0.11 | 7.10% | 1.55 | 1.68 | 1.54 |
| Jul 22, 2024 | 1.60 | 0.13 | 8.84% | 1.47 | 1.60 | 1.47 |
| Jul 19, 2024 | 1.53 | -0.04 | -2.55% | 1.57 | 1.60 | 1.52 |
| Jul 18, 2024 | 1.61 | -0.07 | -4.17% | 1.68 | 1.76 | 1.61 |
| Jul 17, 2024 | 1.74 | -0.06 | -3.33% | 1.80 | 1.87 | 1.70 |
| Jul 16, 2024 | 1.85 | 0.15 | 8.82% | 1.70 | 1.89 | 1.70 |
| Jul 15, 2024 | 1.70 | 0.04 | 2.41% | 1.66 | 1.73 | 1.66 |
| Jul 12, 2024 | 1.68 | 0.00 | 0.00% | 1.68 | 1.74 | 1.63 |
| Jul 11, 2024 | 1.67 | 0.09 | 5.70% | 1.58 | 1.71 | 1.57 |
| Jul 10, 2024 | 1.56 | -0.02 | -1.27% | 1.58 | 1.62 | 1.54 |
| Jul 9, 2024 | 1.58 | 0.03 | 1.94% | 1.55 | 1.68 | 1.54 |
| Jul 8, 2024 | 1.59 | 0.18 | 12.77% | 1.41 | 1.59 | 1.41 |
| Jul 5, 2024 | 1.43 | 0.00 | 0.00% | 1.43 | 1.49 | 1.39 |
| Jul 3, 2024 | 1.48 | 0.04 | 2.78% | 1.44 | 1.50 | 1.38 |
| Jul 2, 2024 | 1.48 | -0.03 | -1.99% | 1.51 | 1.52 | 1.39 |
| Jul 1, 2024 | 1.56 | 0.17 | 12.23% | 1.39 | 1.56 | 1.38 |
| Jun 28, 2024 | 1.40 | 0.03 | 2.19% | 1.37 | 1.43 | 1.26 |
| Jun 27, 2024 | 1.35 | 0.08 | 6.30% | 1.27 | 1.37 | 1.16 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Lyell Immunopharma, Inc. Company profile
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc is a T cell reprogramming company. The Company offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. It builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). It offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. It utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Lyell Immunopharma Inc revenues increased 44% to $7.8M. Net loss increased 1% to $166.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $11.3M to $28.4M (expense), General and administrative - Balanc increase of 39% to $28.8M (expense).
| Industry: | Bio Therapeutic Drugs |
201 Haskins Way
Suite 301
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com